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INTRODUCTION 
 
Recent advances in neurosciences have demonstrated that peripheral 
tissue injury may lead to long alterations in central processing with reduction in 
threshold, amplification of response, expanded receptive fields and after 
discharges of dorsal horn neurons 6, 25. Experimental studies have revealed that 
the input which are innocuous may also begin to pain. Comparable alterations 
may also occur in humans following surgical trauma, resulting in amplification 
and prolongation of postoperative pain6, 25, 26.  Nociceptive stimulation causes 
neurotransmitter release which is coupled with activation of voltage-dependent 
calcium conductance in synaptic terminal membranes of neurons. A disruption 
of calcium influx into cells interferes with normal sensory processing and 
contributes to antinociception.  
Peripheral tissue injury provokes both peripheral and central 
sensitization. Peripheral sensitization is a reduction in the threshold of 
nociceptor - afferent peripheral terminals, and central sensitization is an 
activity - dependent increase in the excitability of spinal neurons. There is 
considerable evidence that excitatory amino acids and neuropeptides are 
involved in nociceptive transmission in the dorsal horn of the spinal cord1, 5. 
The actions of excitatory amino acids are mediated by the N-methyl D-
aspartate (NMDA) receptor and non-NMDA receptors. Activation of NMDA 
receptors leads to Ca 2+ entry into the cell and initiates a series of central 
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sensitization such as windup and long term potentiation in the spinal cord in the 
responses of cells to prolonged stimuli. This activation of NMDA receptors is 
responsible for the induction and the maintenance of enhanced responses for 
prolonged periods of time. This central sensitization may be prevented not only 
with NMDA antagonists such as ketamine and dextrometorphan, but also with 
calcium channel blockers that block Ca2+ entry into cells. This study was 
therefore designed to evaluate the analgesic efficacy of bupivacaine and 
verapamil mixture given through lumbar epidural route in patients undergoing 
elective orthopaedic lower limb surgeries and comparing the quality of 
analgesia with epidural plain bupivacaine. 
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AIMS AND OBJECTIVES 
 
1. To evaluate the analgesic efficacy of bupivacaine and verapamil mixture 
given through lumbar epidural route for postoperative analgesia in 
patients undergoing elective orthopaedic lower limb surgeries. 
2. To compare the quality of analgesia of epidural bupivacaine - verapamil 
mixture with epidural plain bupivacaine.  
3. To evaluate the hemodynamic response of epidural verapamil.  
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PHYSIOLOGY OF PAIN 
 The International Association for the Study of Pain (IASP) defines pain 
as "an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage or described in terms of such damage". This definition 
recognizes the interplay between the objective, physiological, sensory aspects 
of pain and its subjective, emotional and psychological components. The 
response to pain can be highly variable among persons as well as in the same 
person at different times.  
 They are of two types - physiological and pathological pain.  
I. PHYSIOLOGICAL PAIN : has been defined by C.M. Woolf 24 as the 
pain which we experience in our everyday lives when exposed to noxious 
stimuli, it is characterised as being: 
1. High threshold 
2. Well localised and transient. 
3. Has a stimulus response relationship similar to that of other 
somatosensations. 
4. Operates as a protective system, warning of contact with 
potentially damaging stimuli 
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This is due to the highly specialised peripheral sensory pathways that 
subserve these different sensations.  
II. CLINICAL PAIN : Clinical pain which arises as a consequence of 
either inflammation due to tissue injury or neuronal injury is pathological. It is 
divided into inflammatory (pain due to tissue damage) and neuropathic pain 
(damage to nervous system). Both inflammatory and neuropathic pain are 
characterised by changes in sensitivity as per Raja S et al 13. 
ALLODYNIA : A stimulus that would never normally produce pain 
begin to do so.  
HYPERALGESIA : Exaggerated response to painful stimuli. They are 
of 2 types   -  Primary Hyperalgesia,  
                      Secondary Hyperalgesia 
 PRIMARY HYPERALGESIA : This refers to changes that occur 
within the site of injury. Within the site of injury, the nociceptors become 
sensitized and is characterised by a decrease in threshold, an augmented 
response to suprathreshold stimuli and occasionally by spontaneous activity.  
SECONDARY HYPERALGESIA : This refers to the changes in the 
preinjured tissue surrounding the site of injury where again the pain threshold 
decreases. Both peripheral and central mechanisms have been suggested in the 
past to explain secondary hyperalgesia. Secondary hyperalgesia is due to 
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peripheral mechanism resulting from the spread of sensitization from adjoining 
nociceptors which were directly injured. In support of a central mechanism for 
secondary hyperalgesia sensitization of dorsal horn spinothalamic neurons to 
mechanical stimuli following cutaneous heat injury and C fibres stimulations 
has been demonstrated.  
 Two mechanisms operate to produce the changes in sensitivity found in 
inflammatory pain.  
A. PERIPHERAL SENSITIZATION : This is due to increased 
transduction sensitivity of high threshold nociceptors, so that they behave like 
low threshold nociceptors as a result of exposure to sensitizing soup.  
 
  
 
 
 
 
 
TISSUE INFLAMMATION SYMPATHETIC TERMINALS
SENSITIZING SOUP
H+, HISTAMINE, PURINES, LEUKOTRIENES, 
NOREPINEPHRINE, POTASSIUM, CYTOKINES, 
BRADYKININS, PG, 5-HT, NEUROPEPTIDES 
TRANSDUCTION
HIGH THRESHOLD 
NOCICEPTORS 
LOW THRESHOLD 
NOCICEPTORS 
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Raja et al13 stated that nociceptors, both A δ and C are characterised by 
high thresholds and require intense stimuli to activate them. After peripheral 
tissue injury, the threshold for eliciting pain decreases both within the area of 
injury - primary hyperalgesia and in the surrounding uninjured tissue - 
secondary hyperalgesia. In the zone of injury, there is increased sensitivity to 
thermal and mechanical stimuli, while in the surrounding tissue, it is to 
mechanical stimuli. Changes in mechanical sensitivity have been more difficult 
to demonstrate, but occurs in joints. Therefore, peripheral sensitization enables 
low intensity stimuli to produce pain by activating A δ and C fibres.  
 B.  CENTRAL   SENSITIZATION : C.J. Woolf 24 describes that the 
change in the excitability of neurons in the spinal cord is triggered by 
outlasting nociceptive afferent inputs. This is characterised by.  
1. Nociceptor input from low threshold mechanoreceptor (Aβ) causing 
hyperexcitability of the dorsal horn neurons in the spinal cord 
(allodynia).  
2. It is responsible for all the changes in the mechanical sensitivity 
occurring in the zone of the secondary hyperalgesia, outside  the site of 
injury. Therefore, central sensitization represents an input in normal low 
threshold A β fibres producing pain due to changes in the sensory 
processing in the spinal cord.  
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CENTRAL SENSITIZATION 
NOCICEPTOR INPUT 
 
ACTIVITY DEPENDENT INCREASE IN EXCITABILITY OF  
DORSAL HORN NEURONS 
 
LOW THRESHOLD MECHANORECEPTORS MODIFIED RESPONSIVENESS 
(Aβ FIBRES)        
PAIN (MECHANICAL                                  
               ALLODYNIA) 
 To summarise, the major and fundamental difference between peripheral 
and central sensitization is as follows: 
 Peripheral sensitization enables low intensity stimuli to produce pain by 
activating sensitized Aδ and C nociceptors which normally have high 
thresholds and require intense stimuli to activate them. Central sensitization on 
the other hand represents an input in normal low threshold Aβ sensory fibres 
producing pain as a result of changes in sensory processing in the spinal cord. 
Sensory processing in the spinal cord can be monitored by studying the 
receptive field properties of the spinal neurons. These are patterns of neural 
activity generated by particular stimuli applied to the periphery and include (i) 
spatial (ii) threshold (iii) temporal element (iv) modality sensitivity as 
described by Willis WD et al19. Receptive field properties of spinal neurons are 
not fixed but can change. Therefore, sensory input is normally too low in 
amplitude to generate an action potential discharge and hence, an output signal 
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from the post synaptic cell. A summation of spatial and temporal elements is 
required to exceed the action potential threshold of the cell. The receptive field 
consists of : 
 CENTRAL PART : It is the firing zone where adequate stimuli will 
generate an action potential discharge.  
 THE SUBLIMINAL ZONE : This surrounds the centre where the 
response evoked in the cell by a peripheral input is subthreshold. This 
subliminal input provides an opportunity for change. Therefore an increase in 
the excitability of the neuron can convert a subthreshold input into a 
suprathreshold response - receptive field plasticity, which will lead to 
hypersensitivity to the subsequent stimuli. This in turn causes expansion of the 
size of the receptive field and increase in the magnitude and duration of 
response to suprathreshold stimuli.  
CELLULAR MECHANISMS OF CENTRAL SENSITIZATION: 
 As described by Thompson et al18 C fibre terminals release both 
excitatory amino acid glutamate and neuropeptides like tachykinins in the 
dorsal horn of the spinal cord. Glutamate can act on both alpha amino-3 
hydroxy-5 methyl-4 isoxazole propionic acid (AMPA) and N-methyl-D 
aspartate (NMDA) receptors on post synaptic membranes of the dorsal horn 
neurons. Normally the ion channel linked to NMDA receptor is blocked by 
Mg++ but the block can be removed by a depolarisation of the cell leading to 
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an influx of Ca++ and Na+ ions causing further depolarisation. The tachykinins 
bind to neurokinin receptors NK and NK2, leading via GTP protein activation, 
to depolarisation and to changes in second messengers. The former will act on 
the NMDA ion channel where as the latter acts indirectly via protein kinase 'c' 
activation. Therefore NMDA receptor and tachykinins receptor blockers can 
prevent the central sensitization, as described by Woolf CJ23 & Thompson 
SWN 18.  
 Evidence of neuroplasticity was shown by Woolf CJ et al22 who 
proposed that the duration of central sensitization may outlast the duration of 
nociceptor input and alterations in central processing may be maintained for 
longer periods by structural and biochemical changes mediated by intracellular 
Ca++ or second messengers.      
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POST OPERATIVE PAIN 
Effects of  Postoperative  Pain:  
Postoperative pain can affect all organ systems and includes  
¾ Respiratory  - Reduced cough, atelectasis, sputum retention and 
hypoxemia. 
¾ Cardiovascular - Increased myocardial oxygen consumption and 
ischemia.  
¾ Gastrointestinal - Delayed gastric emptying, reduced gut motility 
and constipation. 
¾ Genitourinary -  Urinary retention. 
¾ Neuroendocrine  - Hyperglycemia, protein catabolism and sodium 
retention.  
¾ Musculoskeletal - Reduced mobility pressure sores and increased 
risk of deep vein thrombosis.  
¾ Psychological - Anxiety and fatigue.  
 
Non-Pharmacological methods of pain relief: 
Preoperative explanation and education, Relaxation therapy, Hypnosis, 
cold or heat, Splinting of wounds, Transcutaneous electrical nerve stimulation 
(TENS).  
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Pharmacological Methods of pain relief: 
i. Simple Analgesia - Paracetamol (parenteral / oral) 
Non - steroidal Anti - inflammatory agents - 
(parenteral / oral). 
ii. Opioids - oral, subcutaneous, intramuscular, intravenous, Patient-
controlled Analgesia (PCA), Epidural or intrathecal.  
iii. Local anaesthetic Agents - Wound infiltration, nerve (or) nerve 
plexus blockade, epidural, intrathecal. 
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BENEFITS OF EPIDURAL ANALGESIA 
Use of perioperative epidural anaesthesia and analgesia especially with a 
local anaesthetic - based analgesic solution can attenuate the pathophysiologic 
response to surgery and may be associated with a reduction in mortality and 
morbidity compared with analgesia with systemic opioids.  
Rodgers et al14 demonstrated through a meta - analysis of randomized 
data (141 trials enrolling 9559 subjects) that perioperative use of neuraxial 
anaesthesia and analgesia versus general anaesthesia and systemic opioids 
reduced overall mortality by approximately 30%. Use of epidural analgesia can 
decrease the incidence of postoperative gastrointestinal, pulmonary and cardiac 
complications.  
Christopherson et al3 demonstrated that use of intra operative regional 
anaesthesia decreases the incidence of postoperative hypercoagulable - related 
events (e.g. Deep vein thrombosis, pulmonary embolism. vascular graft 
failure). 
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POSTOPERATIVE ANALGESIA IN ORTHOPAEDICS 
 Postoperative pain is of major concern after orthopaedic lower limb 
surgery. Moderate to severe at rest, it is exacerbated on movement and 
particularly after hip and knee surgery and by severe reflex muscular spasms. 
This not only causes patient discomfort but also compromises the early 
physical therapy, the most influential factor on rapid postoperative 
rehabilitation and ambulation.  
 Postoperative pain relief can be achieved by a number of techniques 
such as intravenous patient controlled analgesia (PCA) with morphine or non-
steroidal anti - inflammatory drugs or epidural analgesia. Effective analgesia 
with epidural or peripheral blockade reduces narcotic requirements, provides 
better analgesia, reduces catabolism and results in improved rates of 
rehabilitation after orthopaedic lower limb surgeries.  
 The benefits of effective postoperative analgesia in orthopaedic 
surgeries was made evident by the fact that it facilitates early ambulation which 
is beneficial in the prophylaxis of deep vein thrombosis, which is a common 
problem  encountered in orthopaedics15. Postoperative modalities like 
pneumatic compression boots, foot pumps, foot exercises, aspirin and low dose 
warfarin (started the day after surgery) can be safely used in conjunction with 
epidural anaesthesia to reduce the incidence of deep vein thrombosis.  
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BUPIVACAINE 
Bupivacaine was introduced by Boaf Ekenstam in 1963.  
Chemical Structure : Bupivacaine hydrochloride is 2- piperidinecarboxamide 
1-butyl-N-(2,6 dimethylphenyl) monohydrochloride, a monohydrate a white 
crystalline powder that is freely soluble in 95% ethanol, soluble in water and 
slightly soluble in chloroform or acetone. 
 
 
 
 Bupivacaine is related chemically and pharmacologically to the amide 
group of local anaesthetics. It is a structural homologue  of mepivacaine.  
Presentation : Bupivacaine hydrochloride is  available in sterile isotonic 
solution with and without epinephrine 1:2,00,000 for injection. 0.25%, 0.5%, 
0.75% concentration containing 2.5mg/ml 5mg/ml, 7.5mg/ml of bupivacaine 
hydrochloride respectively. Sodium chloride, sodium hydroxide + hydrochloric 
acid for pH adjustment. Methylparaben 1mg/ml added as preservative. 0.5% 
(Hyperbaric) solution containing 80mg/ml of glucose (with a specific gravity of 
1.026) - for intrathecal use.  
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Mechanism of Action:  
 Local anaesthetics diffuse in their nonionized form through neural 
sheaths and the axonal membrane to the internal surface of cell membrane 
sodium ion channels where they combine with hydrogen ions to form a cationic 
species which enters the internal opening of the sodium ion channel and 
combines with a receptor. This produces blockade of the sodium ion channel 
thereby decreasing sodium conductance and preventing depolarisation of the 
cell membrane.  
Pharmacological actions: 
a) Central Nervous System (CNS) : The principal effect of bupivacaine is 
reversible neural blockade, this leads to a characteristically biphasic 
effect on the CNS.  
¾ Initially excitation : Lightheadedness, dizziness, visual and 
auditory disturbances and seizures occurs due to blockade of 
inhibitory pathways in the cortex.   
¾ With increasing doses : CNS depression occurs. Depression of 
both facilitatory and inhibitory pathways leading to 
drowsiness, disorientation and coma. 
¾ Local anaesthetic agents block neuromuscular transmission 
when administered intra-arterially (formation of 
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neurotransmitter, receptor and local anaesthetic complex 
which has negligible conductance) 
b ) Cardiovascular System (CVS) : It binds specifically to 
myocardial proteins. In toxic concentrations, the drug decreases the peripheral 
vascular resistance and myocardial contractility producing hypotension and 
possibly cardiavascular collapse. (Cardiotoxic only in high doses). 
Routes of Administration: Topical, Infiltration, Intrathecal, Epidural.  
Doses : 2mg/ kg (with or without adrenaline) 
Pharmacokinetics :  
Absorption : The absorption of local anaesthetic agents is related to  
1. The site of injection (intercostal > epidural > brachial plexus > 
subcutaneous).  
2. The dose-linear relationship exists between the total dose and 
the peak blood concentration achieved.  
3. Addition of adrenaline to bupivacaine solutions doesn't 
influence the rate of systemic absorption as: 
- the drug is highly lipid soluble and therefore uptake into fat is 
rapid.  
- the drug has a direct vasodilatory effect.  
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Distribution :  95% protein bound in plasma. The volume of distribution is 
41-103 litres.   
Metabolism : Occurs in Liver by N-dealkylation primarily to 
pipcolyloxylidine. N-desbutyl bupivacaine and 4-hydroxy 
bupivacaine are also formed.  
Excretion :  16% - unchanged form 
 5% - pipcolyloxylidine in Urine 
Clearance rate - 0.47 litres/ min 
Elimination half life - 0.31- 0.61 hours.   
Pharmacodynamics : pKa of bupivacaine is 8.1, Heptane : Buffer 
partition coefficient is 27.5.  
 The onset and duration of conduction blockade is related to the pKa, 
lipid solubility and the extent of protein binding of the drug.  
- A low pKa and high lipid solubility are associated with a rapid onset 
time.  
- High degree of protein binding is associated with a long duration of 
action.  
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Toxicity / side effects: 
i) Allergic reactions to amide - type local anaesthetics.  
ii) No longer recommended for intravenous regional blockade - as 
refractory cardiac depression leading to death has been reported.  
Contra-indications:  
i) Obstetrical paracervical block - Resulted in fetal bradycardia & 
death.  
ii) Known hypersensitivity to any amide group of local anaesthetics.  
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VERAPAMIL 
 Verapamil is an L-type calcium channel blocker approved by FDA in 
1981.  
Chemical Structure : A synthetic papaverine derivative. 
 
 
Systemic (IUPAC) name -  
2-(3,4-dimethoxyphenyl)-5[2-(3, 4-dimethoxyphenyl)  
ethyl-methyl-amino] -2-(1-methylethyl)pentanenitrile 
Formula - C27 H38 N2 O4  
Molecular mass - 454.602g/mol  
Preparations :  Oral  - 40/80/120/160/180/240 mg tablets 
Intravenous injection - Racemic mixture of 
verapamil hydrochloride (2.5 mg / ml).  
Mechanism of Action:   
 Competitive blockade of cell membrane slow calcium ion channels  
(L-type) leading to a decreased influx of Ca2+ ions into vascular smooth muscle 
and myocardial cells and cells of intracardiac conduction system. This results 
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in electromechanical decoupling, inhibition of contraction and relaxation of 
cardiac and smooth muscle fibres.  
Pharmacological actions: 
Cardiovascular System (CVS): Verapamil is a class IV anti-arrhythmic agent; it 
decreases automaticity and conduction velocity and increases refractory period. 
Atrio-ventricular conduction is slowed; the drug appears to be taken up and 
bound specifically by atrioventricular nodal tissue. The drug causes a decrease 
in the systemic vascular resistance and a potent coronary artery vasodilator. It 
has a negative dromotropic and inotropic effect which are enhanced by 
acidosis.  
Central Nervous System (CNS) : It causes cerebral vasodilation  
- Verapamil has a local anaesthetic action that is 1.6 times that of 
procaine on an equimolar basis.  
Genitourinary - Verapamil decreases renovascular resistance.  
Routes of Administration / Doses:  
• Adult oral dose - 240- 480 mg daily in 2- 3 divided doses. 
• Intravenous dose - 5 - 10 mg administered over 30 seconds 
 Peak effect after IV injection occurs at 3-5 minutes and the duration of 
action is 10-20 minutes.  
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Pharmacokinetics: 
Absorption :  Oral bioavailability - 35.1% due to significant first pass 
metabolism.  
Distribution: 90% protein bound in the plasma.  
volume of distribution - 3.1 - 4.9 L/kg 
Metabolism : By demethylation and dealkylation in liver.  
  Twelve inactive metabolites [though one metabolite - 
norverapamil has 20% of vasodilating activity of parent drug.] 
Half - Life : 2.8 - 7.4 hours 
Excretion : 70% dose is excreted in urine, 16% in faeces  
Clearance is 6.8 - 16.8 ml / min / kg. 
Adverse Effects: Constipation, dizziness, headache, nausea, edema, 
hypotension, AV block, bradycardia and heart failure.  
Contra-indications:  
1. Acute myocardial infarction  
2. Severe congestive cardiac failure  
3. Severe left ventricular dysfunction  
4. Cardiogenic shock 
5. Severe hypotension 
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6. Second or third degree AV block  
7. Sick sinus syndrome 
8. Accessory bypass tract (WPW syndrome & LGL syndrome) 
 
Therapeutic uses: 
i. Anti-anginal  -   chronic stable angina  
                          vasospastic angina.  
ii. Antiarrhythmic - paroxysmal supraventricular tachycardia, atrial 
fibrillation & atrial flutter with rapid ventricular response  
(refractory to digitalis).   
iii. Mild to moderate hypertension.  
Anaesthetic considerations: 
i. Effects of volatile anaesthetic agents and β- blockers on myocardial 
contractility and conduction are synergistic with those of verapamil - 
caution should be exercised when these combinations are used.  
ii. Verapamil increases the serum concentrations of co-administered 
digoxin.  
iii. Chronic exposure to the drug may potentiate the actions of both 
depolarising and non depolarising muscle relaxants.  
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iv. Verapamil attenuates the pressor response to laryngoscopy and 
intubation.  
v. Verapamil and dantrolene administered concurrently in animals 
cause hyperkalemia leading to ventricular fibrillation.  
vi. Verapamil is not removed by hemodialysis.  
Research Studies: 
i. Antinociceptive effect of verapamil8,10,11,12,16. 
ii. Anti-manic effect especially in pregnant mothers (with no 
teratogenecity).  
iii. Uses in cell biology27 - an inhibitor of drug efflux pump proteins 
such as P-glycoprotein which will be useful as many tumour cell 
lines overexpress drug efflux pumps, limiting the effectiveness 
also used in fluorescent cell sorting for DNA content as it blocks 
efflux of a variety of DNA binding fluorochromes such as 
Hoechst 33342.  
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REVIEW OF LITERATURE 
Antinociceptive effects of Ca2+ channel blockers: 
 Miranda, et al 12 in 1992, demonstrated the antinociceptive action of 
four Ca2+ channel blockers, Nifedipine, Nimodipine, Verapamil and 
Diltiazem. He evaluated and compared to that of morphine using three 
algesiometric tests in mice and rats, namely, formalin, writhing and modified 
hot-plate test. Dose-response curves for all the drugs tested were similar and a 
significant dose-dependent antinociceptive action was evident in the formalin 
and writhing tests. However, in the hot-plate test, only nimodipine exhibited a 
significant analgesic effect, confirming the misleading results previously 
reported for this test. The findings suggest a pharmacological role of Ca2+ 
channel blockers in the modulation of antinociception under acute conditions.  
The analgesic action of Ca2+ channel blockers could be mediated by an 
increase in the nociceptive threshold resulting from interference with Ca2+ 
influx at opioid receptors, because Ca2+ influx is critical for the release of 
neurotransmitters and other substances implicated in nociception and 
inflammation. He suggested that if a substance has a Ca2+ channel blocking 
effect, it should probably have some antinociceptive properties.  
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Effects of verapamil on Spinal Anesthesia with Local Anesthetics: 
 Keiichi Omote, et al10 in 1995, demonstrated to investigate the effects 
of the intrathecal calcium channel blocker, verapamil, on the spinal anesthesia 
from lidocaine and tetracaine. Male Sprague-Dawley rats were chronically 
implanted with lumbar intrathecal catheters. Tail-flick (TF) and mechanical 
paw pressure (MPP) tests were used to assess thermal and mechanical 
nociceptive threshold, respectively. Motor function was assessed using a 
modified Langerman's scale. Intrathecal lidocaine or tetracaine alone showed 
the prolongation of TF latency, the increase of MPP threshold, and the increase 
in motor function scale in a time - and dose - dependent manner.  
Although intrathecal verapamil alone demonstrated neither sensory nor 
motor block at the doses used (50-200µg), the combination of lidocaine (20, 
50, 100, or 200 µg) or tetracaine (10, 20, 50, or 100 µg) and verapamil (50 µg) 
produced the more potent and prolonged antinociception and motor block when 
compared with local anesthetics alone. He interpreted these results to indicate 
that the intrathecal calcium channel blocker, verapamil, potentiates spinal 
anesthesia with local anesthetics.  
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Local Anesthetic Effects of Calcium Antagonists on Extracted Rabbit 
Vagus Nerve: 
Kokubu Masahiro et al11 in 1999, demonstrated the local anesthetic 
effects of calcium antagonists (diltiazem, verapamil, and nicardipine) on 
extracted rabbit vagus nerve and their binding ability to the phospholipid 
membrane model were examined by 1H-NMR spectroscopy. Effective 
concentrations of these drugs for vagus nerve blockade were examined with 
12-14V electrical stimuli. The minimum effective concentration of calcium 
antagonist which completely blocked the compound action potential was 
0.5mM for diltiazem, and 0.2mM for verapamil. Nicardipine did not show any 
conduction blocking effect at 1.0mM.  
Local anesthetic effects of ditiazem and verapamil were characterized by 
a slower onset (over 20min) and longer duration (over 30 min) compared with 
lidocaine. The local anesthetic effects of diltiazem and verapamil may be due 
to the SA and AV nodal blocking effect and reductions in the ventricular rate 
by these drugs. However, in the SA and AV nodes, depolarization is largely 
dependent on the movement of Ca2+ through the slow channel. The results of 1 
H-NMR spectroscopy indicated that poor electrostatic binding with the 
phospholipid membrane occured only with diltiazem. Local anesthetic effects 
of calcium antagonists may not be based on electrostatic binding with the nerve 
membrane as in the case of local anesthetics.    
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Epidural Verapamil Reduces Analgesic consumption After Lower 
Abdominal Surgery: 
Huhn Choe, et al8 in 1998, demonstrated the possible role of the 
calcium channel blocker, verapamil, in postoperative pain in a double-blind 
study.  One hundred patients (ASA physical class I or II) scheduled for lower 
abdominal surgery were randomly assigned to one of four groups. Group-1 
received 10mL of 0.5% epidural bupivacaine injected 15 min before incision, 
followed by 10 mL of epidural normal saline 30 min after incision. Group-2 
received 10 mL of epidural normal saline injected before incision, followed by 
10 mL of 0.5% epidural bupivacaine 30 min after incision. Group 3 received 10 
mL of 0.5% epidural bupivacaine plus 5 mg of verapamil injected before 
incision, followed by 10 mL of epidural normal saline 30 min after incision. 
Group-4 received the same drugs as Group 3, in the reverse order.  
Pain and mood numeric rating scores, sedation scores, Prince Henry 
scores, patient-controlled cumulative postoperative analgesic consumption, and 
the incidence of side effects were assessed 2, 6, 12, 24, and 48h after the 
operation in each group. Cumulative postoperative analgesic consumption in 
Groups 3 and 4 was significantly lower (P<0.05) than that in Groups 1 and 2, 
24 and 48 h after surgery. There were no differences in the pain, mood, and 
sedation scores and the incidence of side effects among the four groups. He 
concluded that epidural verapamil decreases postoperative pain, possibly by 
interfering with normal sensory processing and by preventing the establishment 
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of central sensitization and the combination, verapamil and bupivacaine 
administered epidurally, resulted in less postoperative analgesic consumption 
than bupivacaine alone.  
Brachial Plexus Anesthesia with Verapamil and / or Morphine: 
Scott S. Reuben, et al16 in 2000, demonstrated the analgesic effects of 
administering morphine, verapamil, or its combination into the brachial plexus 
sheath with lidocaine in 75 patients undergoing upper extremity orthopedic 
surgery. All patients received brachial plexus anesthesia with 40 mL of 1.5% 
lidocaine and epinephrine 5 µg/ mL. In addition, patients were randomized to 1 
of 5 groups: Group 1 received IV saline, Group 2 received IV verapamil 2.5 mg 
and morphine 5 mg; Group 3 received IV verapamil 2.5 mg and morphine 5 mg 
was added to the lidocaine solution; Group 4 received IV morphine 5 mg and 
verapamil 2.5 mg was added to the lidocaine solution; and Group 5 received 
verapamil 2.5 mg and morphine 5 mg were added to the lidocaine solution.  
   Postoperatively, patients were rated their pain scores (0 -10) at 1, 6, 12, 
and 24 h. Patients were instructed to take 1 acetaminophen 325 mg/ oxycodone 
5 mg tablet every 3 h whenever the pain score exceeded 3. Analgesic duration 
was significantly increased in those patients receiving brachial plexus blocks 
with morphine (Groups 3 and 5) (P <0.005). The total 24h acetaminophen 
/oxycodone use was also less in Groups 3 and 5 (P < 0.03). Duration of 
anesthesia (time of abolition of pinprick response) was significantly increased 
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in those patients receiving brachial plexus blocks with verapamil (Groups 4 and 
5) (P = 0.002). He concluded that the addition of verapamil to brachial plexus 
block with lidocaine can prolong the duration of sensory anesthesia, but it had 
no effect on analgesic duration of 24 h analgesic use.  
The effects of verapamil and nimodipine on bupivacaine-induced 
cardiotoxicity in rats: an in vivo and in vitro study: 
H Adsan, et al9 in 1998,  compared the effects of verapamil or 
nimodipine pretreatment on bupivacaine-induced cardiotoxicity. In the in vivo 
study, the dose-response curve for the 50% lethal dose (LD50) of bupivacaine 
was determined for rats. Two separate groups of rats were pretreated with i.v. 
verapamil 150 µg/kg (n=35) or i.v. nimodipine 200 µg/kg (n=35). Each 
pretreatment group was then subdivided into four groups of at least four rats 
each. Three minutes after pretreatment, bupivacaine was administered to each 
of four groups in doses of 2.5, 3.0, 3.25, and 3.5 mg/kg, respectively, both 
verapamil and nimodipine pretreatment increased the LD50 and 95% 
confidence intervals for bupivacaine and increased survival.  
In the in vitro study, the effects of verapamil or nimodipine perfusion on 
bupivacaine cardiotoxicity (negative chronotropic, negative inotropic, and 
arrhythmogenic effects) and coronary perfusion pressure (CPP) were 
investigated in isolated, perfused rat heart preparations. Depression of heart 
rate, contractile force, and CPP, and the incidence of arrhythmias caused by 
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bupivacaine alone were similar to those caused by bupivacaine after verapamil 
pretreatment. In contrast, bupivacaine induced less negative chronotropic 
effects (P < 0.05, paired t- test) and arrhythmias (P<0.05, chi2 analysis) after 
nimodipine pretreatment. The results of this study demonstrated that both 
verapamil and nimodipine pretreatment decrease bupivacaine-induced 
cardiotoxicity in vivo, whereas only nimodipine pretreatment decreased 
bupivacaine- induced cardiotoxicity and arrhythmias in vitro. Implications : In 
this experimental study consisting of two stages (in vivo and in vitro), he 
compared the effects of two calcium channel-blocking drugs (verapamil and 
nimodipine) on bupivacaine toxicity. Bupivacaine is a local anesthetic 
frequently used in clinical practice, and cardiotoxicity is one of its severe 
side effects. Verapamil and nimodipine were both effective in decreasing 
bupivacaine cardiotoxicity in this rat model.  
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MATERIALS AND METHODS 
 The study population consisted of 40 ASA I & II patients in the age 
group of 18 years to 65 years admitted to undergo elective orthopaedic lower 
limb surgeries at Govt. Stanley Hospital, Chennai. After getting approval by 
the institutional ethics committee and after obtaining written informed consent 
from each patient the study was conducted.  
Exclusion Criteria: 
1. Age more than 65 yrs.  
2. Systemic Hypertension  
3. Ischemic heart disease / Rheumatic heart diseases 
4. Sinus bradycardia / heart blocks/ conduction defects 
5. Patients on Digitalis, calcium channel blockers and β- blockers.  
6. Preoperative hypotension 
7. Local infection at lumbar area 
8. Pre-existing neurological disorders 
9. Coagulation defects & patients on anticoagulants 
10. Patient refusal. 
 
Preoperative Assessment: 
 All the patients were examined prior to surgery. Routine clinical 
examination, Biochemical investigations, Electrocardiogram (12 leads) and 
chest X-ray were examined thoroughly for the conduct of anaesthesia.  
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Conduct of Anaesthesia: 
 Patients were allocated randomly in a double binded fashion into two 
equal groups (20 in each group). Group P (placebo) received 2 ml of Normal 
Saline  along with the first dose of  epidural 0.5% bupivacaine.  Group V 
(Verapamil) received 5 mg (2ml) of  injection Verapamil epidurally along with 
the first dose of 0.5% bupivacaine.  
 No premedication was given. On arrival in the operating room, baseline 
cardiorespiratory parameters viz., Heart rate (HR), Systolic blood pressure 
(SBP), Diastolic Blood Pressure (DBP), Mean Arterial Pressure (MAP) and 
Respiratory rate (RR) were recorded. 
 A good intravenous access was established at the non-operative side 
forearm of the patient using 18 G IV cannula. Preloading was done with 
crystalloids (10 ml/kg).  
 With the patient in sitting posture, after informing the procedure to the 
patient & under strict aseptic precautions, epidural space was identified at L3-
L4 or L2 - L3 interspace using 17G Tuohy needle by Loss of Resistance 
technique. 19G epidural catheter was threaded in a cephalad direction & 3-4 
cm catheter length was kept inside the epidural space. A test dose of 3 cc of 
1.5% lignocaine with adrenaline (5µg/ml) was given. Epidural catheter was 
fixed and secured with tapes. Patient turned into decubitus position.  
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 A standard anaesthetic technique was followed in all patients.  
Epidural 1st dose - 14 ml of 0.5% bupivacaine + 2 ml of placebo or  
injection verapamil. 
Epidural 2nd dose- 6 ml of 0.5% bupivacaine.  
Epidural 3rd dose -  6 ml of 0.25% bupivacaine.   
 Epidural 2nd dose was given exactly 60 minutes after the first dose and 
epidural 3rd dose was given exactly 60 minutes after the epidural 2nd dose for 
all patients according to the duration of surgery. 
 Patients with duration of surgery between 2 - 2:30 hours requiring 
standard 3 doses of epidural local anaesthetics were only taken up for study. 
Unanticipated prolonged duration of surgery (requiring more than 3 doses) 
were excluded from the study.  
 Intra-operatively the patient was monitored with Electro cardiogram 
(ECG), Non-invasive blood pressure (NIBP), Pulseoximetry (SPO2) and urine 
output. During the entire operative procedure. Heart rate (HR). Systolic Blood 
pressure (SBP), Diastolic Blood pressure (DBP), mean arterial pressure (MAP), 
respiratory rate (RR) were continuously monitored & recorded every 5 
minutes. All patients were given oxygen  supplementation (4-5 L/min) through 
hudson's face mask. All the patients were given a dose of anxiolytic with 
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Injection Midazolam 0.05 mg/kg IV. No intravenous opioid analgesics were 
supplemented during the study.  
 Intravenous fluid management was done based on mean arterial blood 
pressure and surgical blood loss.  
Post-operative Monitoring: 
 Postoperatively the patient was transferred to the recovery room and 
observed continuously for 60 minutes. Patient was then shifted to the 
postoperative ward where pulse rate, systolic blood pressure, diastolic blood 
pressure and respiratory rate were recorded at 2, 6, 12, 24, 48 hour intervals. 
The patients were assessed by the same observer in the postoperative period 
who was blinded for the group assignment. The intensity of pain was measured 
by using the verbal rating pain scale at 2, 6, 12, 24, 48 hour intervals. 
Pain Score (Verbal Rating Scale) 
Grade 0 - No complaint of pain 
Grade 1 - Patient complaints of pain but tolerable (Mild pain) 
Grade 2 - Patient complaining of severe pain and demands relief.     
   (Moderate pain) 
Grade 3 - Patient restless and sreaming with pain. (Severe pain) 
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 When the patient complained of pain i.e., the pain intensity was assessed  
based on Verbal Rating Scale and if the pain score reached 1, patient was given 
injection. Diclofenac sodium 75 mg intramuscularly. The time of first rescue 
analgesia (TFA) was calculated from the time of injection of the study drug in 
the epidural space to the time when the verbal rating pain score reached 1 in the 
postoperative period. 
 Number of supplementary analgesics (Injection Diclofenac sodium 75 
mg IM) required by each patient for a period of 48 hours was noted in both the 
groups. Occurrence of significant side effects like hypotension, bradycardia 
were noted down.  
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OBSERVATIONS 
STATISTICS AND ANALYSIS: 
 Forty patients posted for orthopaedic lower limb surgeries of ASA I & II 
were taken up for the study. They were allocated randomly in a double - 
blinded fashion into two groups in equal number of 20 each. Group P recieved 
2 ml of placebo along with the first dose of epidural 0.5% bupivacaine and 
group V received 2 ml (5mg) of injection verapamil along with the first dose of 
epidural 0.5% bupivacaine. A standard anaesthetic technique was followed in 
all patients. The patients were assessed by the same observer in the 
postoperative period who was blinded for the group assignment.  
 All the datas were expressed as mean + standard deviation (SD). 
Qualitative variables were compared with 'chisquare test'. Quantitative 
variables were compared with the 'student 't' test'.  
 The level of statistical significance was set at  
 ** P < 0.01  - Significance at 1% level. 
 * P <0.05   - Significance at 5% level. 
    P> 0.05   - Not Significant at 5% level. 
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Demographic Profile:  
TABLE 1 
PATIENT CHARACTERISTICS 
 
Group 
Group P Group V S. No. Parameters 
Mean ± SD Mean ± SD 
p value 
1. Age (yrs) 35.10 ± 9.26 37.65 ± 11.60 0.447 
2. Height (cms) 166.50 ± 4.72 166.30 ± 4.66 0.893  
3. Weight (kgs) 62.25 ± 6.41 62.80 ± 8.46 0.818 
4. Duration of Surgery (hrs) 2.15 ± 0.09 2.15 ± 0.08 0.913 
 
 Thus the demographic profile and duration of Surgery (hrs) were 
comparable between the two groups. P value was not significant.  
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LIST OF ORTHOPAEDIC LOWER LIMB SURGERIES 
 
NO. OF CASES S. 
No. 
DIAGNOSIS AND SURGICAL 
PROCEDURES 
GROUP P GROUP V
1. Fracture shaft of femur - ORIF with 
interlocking nailing 
11 9 
2. Fracture both bones leg - ORIF with 
intramedullary nailing 
3 4 
3. Fracture neck of femur - Hemiarthroplasty 3 4 
4. Supracondylar fracture femur - ORIF with 
dynamic condylar screw (DCS) 
2 3 
5. Fracture Patella - ORIF with Tension band 
wiring 
1 - 
 TOTAL CASES 20 20 
 
(ORIF - Open Reduction and Internal Fixation) 
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TABLE 2 
HEART RATE 
 
Group 
Group P Group V S. No. 
Parameters 
(Minutes) 
Mean ± SD Mean ± SD 
p value 
1. HR PRE - OP 101.70 ± 7.83 100.70 ± 8.54 0.702 
2. HR10 96.05 ±  5.98 94.60 ± 6.59 0.471 
3. HR20 90.80 ± 7.09  97.20 ± 6.60 0.465 
4. HR30 87.55 ± 4.77  86.15 ± 4.11 0.326 
5. HR40 86.45 ± 5.71 85.95 ± 5.31 0.776 
6. HR50 85.10  ± 6.16 84.85 ± 6.71 0.903 
7. HR60 85.05 ± 7.42 83.75 ± 7.44 0.583 
8. HR70 83.90  ± 7.78 81.35 ± 7.24 0.290 
9. HR80 82.95 ± 7.16  82.10 ± 6.88 0.704 
10. HR90 82.95 ± 7.16 82.70 ± 7.98 0.917 
11. HR100 84.25  ± 6.58 85.90 ± 6.98 0.447 
12. HR110 88.40  ± 5.08 88.80 ± 4.96 0.802 
13. HR120 92.00 ± 4.84 89.00 ± 4.59 0.052 
14. HR130 90.85 ± 4.53 88.50 ± 3.09 0.063 
15. HR140 91.50  ± 5.25 91.10 ± 5.28 0.811 
16. HR150 96.40  ± 5.04 98.35 ± 6.23 0.283 
 
 P value is not significant among both the groups at any point of time 
during intraperative heart rate  monitoring.  
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TABLE 3 
SYSTOLIC BLOOD PRESSURE 
Group 
Group P Group V S. No. 
Parameters 
(Minutes) 
Mean ± SD Mean ± SD 
p value 
1. SBP PRE-OP 129.25 ± 4.67 127.60 ± 4.52 0.263 
2. SBP10 119.60  ± 3.91 116.20 ± 3.41 0.006** 
3. SBP20 105.40 ±  6.24 102.30 ± 5.35 0.095 
4. SBP30 108.45 ± 6.75 106.95 ± 6.38 0.474 
5. SBP40 110.45 ± 6.56 113.10 ± 4.53 0.145 
6. SBP50 112.85 ± 7.25 112.70 ± 6.10 0.944 
7. SBP60 114.35 ± 4.86 114.20 ± 4.40 0.919 
8. SBP70 113.25 ± 5.06 112.25 ± 4.92 0.530 
9. SBP80 113.60 ± 5.39 115.50 ± 4.36 0.228 
10. SBP90 112.65 ± 4.75 114.10 ± 3.84 0.295 
11. SBP100 112.70 ± 6.58 108.35 ± 23.43 0.429 
12. SBP110 118.15 ± 3.45 116.05 ± 4.65 0.113 
13. SBP120 120.75 ± 4.69 119.75 ± 4.71 0.505 
14. SBP130 116.60 ± 3.19 117.60 ± 3.22 0.330 
15. SBP140 118.40 ± 5.47 119.40 ± 4.16 0.519 
16. SBP150 124.80 ± 2.17 125.15 ± 2.48 0.637 
 
 
(** P < 0.01 - Significant) 
 Systolic blood pressure (SBP) monitoring between two groups were 
found to be insignificant except during 10 mins. interval (with a significant  P 
value P< 0.01)  
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FIGURE - 3 
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TABLE 4 
DIASTOLIC BLOOD PRESSURE 
Group 
Group P Group V S. No. 
Parameters 
(Minutes) 
Mean ± SD Mean ± SD 
p value 
1. DBP PRE-OP 83.15 ± 3.00 81.45 ± 2.96 0.079 
2. DBP10 74.05 ± 4.65 70.25 ± 3.42 0.005** 
3. DBP20 62.75 ± 6.62 58.80 ± 4.86 0.038* 
4. DBP30 64.95 ± 6.69 63.70 ± 6.22 0.544 
5. DBP40 67.60 ± 4.16 68.35 ± 4.89 0.604 
6. DBP50 68.05 ± 5.09 67.70 ± 5.62 0.838 
7. DBP60 70.45 ± 4.35 69.65 ± 4.31 0.562 
8. DBP70 68.85 ± 5.35 67.40 ± 4.64 0.366 
9. DBP80 69.45 ± 4.73 69.90 ± 4.39 0.757 
10. DBP90 69.10 ± 3.71 69.15 ± 4.21 0.968 
11. DBP100 69.35 ± 5.31 69.20 ± 6.35 0.936 
12. DBP110 73.30 ± 3.63 70.95 ± 3.68 0.049* 
13. DBP120 74.40 ± 5.17 73.65 ± 4.80 0.638 
14. DBP130 72.05 ± 3.82 71.25 ± 3.96 0.519 
15. DBP140 73.60 ± 5.83 73.70 ± 4.52 0.952 
16. DBP150 79.15 ± 2.48 78.95 ± 3.72 0.342 
 
(* P < 0.05, ** P < 0.01 - significant) 
 Intraoperative Diastolic Blood Pressure (DBP), monitoring between the 
two groups were found to be insignificant except during 10 mins, 20 mins and 
110 minutes, which were only found to have a significant P Value.  
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TABLE 5 
MEAN ARTERIAL BLOOD PRESSURE 
 
Group 
Group P Group V S. No. 
Parameters 
(Minutes) 
Mean ± SD Mean ± SD 
p value 
1. MAP PRE-OP 98.50 ± 3.33 96.35  ± 4.06 0.075 
2. MAP10 89.10 ± 4.14 85.65 ± 2.91 0.004** 
3. MAP20 77.00 ± 6.18 73.05 ± 5.04 0.033* 
4. MAP30 79.35 ± 6.47 78.20 ± 6.08 0.566 
5. MAP40 82.00 ± 4.50 83.30 ± 4.11 0.346 
6. MAP50 82.95 ± 5.59 82.65 ± 5.52 0.865 
7. MAP60 85.55 ± 5.09 84.65 ± 4.09 0.542 
8. MAP70 83.60 ± 4.90 82.40 ± 4.48 0.424 
9. MAP80 84.25 ± 4.63 85.15 ± 3.92 0.511 
10. MAP90 84.55 ± 4.71 84.10 ± 3.73 0.739 
11. MAP100 83.85 ± 5.47 84.35 ± 5.42 0.773 
12. MAP110 88.50 ± 3.82 86.00 ± 3.68 0.042* 
13. MAP120 89.70 ± 5.06 88.95 ± 4.45 0.622 
14. MAP130 87.25 ± 3.01 86.90 ± 3.40 0.732 
15. MAP140 88.10 ± 5.61 89.20 ± 3.89 0.475 
16. MAP150 94.30 ± 2.36 94.30 ± 3.11 1.000 
 
(* P < 0.05, ** P < 0.01 - Significant) 
 Intra operative Mean Arterial pressure (MAP) recordings between the 
two groups were found to be insignificant except during 10 mins, 20 mins and 
110 minutes.  
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 Intraoperative monitoring of heart rate (HR), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) between 
the two groups (Group P & Group V) were found to be insignificant at most of 
the time intervals except at 10, 20, 110 mins. intervals which were only found 
to be significant.  This demonstrates that the hemodynamic stability maintained 
in verapamil group is comparable to that of the hemodynamic stability 
maintained in placebo group throughout the intraoperative period.  
TABLE 6 
RESPIRATORY RATE 
Group 
Group P Group V S. No. 
Parameters 
(Minutes) 
Mean ± SD Mean ± SD 
p value 
1. RR PRE-OP 15.30 ± 1.13 15.15 ± 1.09 0.671 
2. RR10 13.30 ± 1.22 14.15 ± 0.93 0.018* 
3. RR20 13.90  ± 0.97 14.10 ± 1.12 0.549 
4. RR30 12.75 ± 0.97 13.10 ± 0.97 0.260 
5. RR40 12.45 ± 0.69 12.60 ± 0.75 0.515 
6. RR50 12.65 ± 1.09 12.55 ± 0.76 0.738 
7. RR60 13.00 ± 0.79 12.95 ± 0.69 0.833 
8. RR70 13.45 ± 0.94 13.25 ± 0.85 0.486 
9. RR80 12.80 ± 1.15 12.95 ± 1.05 0.669 
10. RR90 12.95 ± 0.94 12.95 ± 0.89 1.000 
11. RR100 13.10 ± 1.12 13.15 ± 1.09 0.887 
12. RR110 13.20 ± 1.15 13.05 ± 1.15 0.682 
13. RR120 13.15 ± 1.39 12.55 ± 0.83 0.105 
14. RR130 13.05 ± 1.32 12.50 ± 1.00 0.145 
15. RR140 13.90 ± 1.07 13.35 ± 0.93 0.092 
16. RR150 14.95 ± 1.15 14.75 ± 1.22 0.508 
 
(* P < 0.05 - Significant ) 
 Comparison of respiratory rate among the two groups were found to be 
insignificant except during 10 mins. interval (*P value at RR 10 minutes < 
0.05)  
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TABLE 7 
PAIN SCORE  (VERBAL RATING SCALE) 
 
Group 
Group P Group V S. No. 
Parameters 
(Hours) 
Mean ± SD Mean ± SD 
p value 
1. PS2 (hrs) 2.75± 0.44 0.00± 0.00 0.001** 
2. PS6 (hrs) 2.00± 0.46 0.45 ± 0.69 0.001** 
3. PS12 (hrs) 2.15± 0.49 1.70 ± 0.57 0.011* 
4. PS24 (hrs) 1.95± 0.69 1.60 ± 0.60 0.094 
5. PS48 (hrs) 1.85± 0.49 0.90 ± 0.31 0.001** 
 
(* P < 0.05, ** P < 0.01 - Significant) 
 
 The postoperative pain score (verbal rating scale) was found to be low at 
all time intervals (2, 6, 12, 24, and 48 hrs) in Group V when compared to group 
P. Significantly low pain scores were observed at 2, 6, 12 and 48 hours 
intervals in patients belonging to group V (P < 0.01 at 2, 6, & 48 hours 
intervals & P <0.05 at 12 hours interval) than group P as shown in figure 7. The 
study demonstrated that pain relief was significantly better (P<0.05) in patients 
who received epidural bupivacaine with verapamil mixture than the patients 
who received epidural bupivacaine with placebo.  
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TABLE 8 
TFA & TOTAL POST - OPERATIVE  
ANALGESIC REQUIREMENTS 
 
Group 
Group P Group V 
S. 
No. 
Parameters 
Mean ± SD Mean ± SD 
p value 
1. Time of First rescue analgesic 
(hrs) 
3.84 ± 0.46 6.42 ± 0.63 0.001** 
2. No. of supplementary analgesic 
doses (Doses for 48 hrs)  
6.35± 0.49 4.25± 0.44 0.001** 
  
(* P < 0.05, ** P < 0.01 - Significant) 
 The mean time of first rescue analgesic (TFA in hours) was found to be 
6.42 ± 0.63 hours in Group V than the 3.84 ± 0.46 hours observed in Group P 
which is statistically significant. (p<0.01). 
 Mean supplementary analgesic doses required in group V for 48 hours - 
4.25 ± 0.44 doses. Mean supplementary analgesic dose required in group P for 
48 hours - 6.35 ± 0.49 doses. The demand for supplementary analgesia over 48 
hours was low in group V than group P with significant statistical difference 
(P<0.01).  
 Chi-square test demonstrated no significant difference among both the 
groups regarding the incidence of side effects. (2 patients in Group P and 1 
patient in Group V developed hypotension). No bradycardia was reported in 
either of the two groups.  
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DISCUSSION 
 Our knowledge of acute pain mechanisms has advanced sufficiently 
over the past decade so that rational rather than empirically derived therapy can 
be used by aiming specifically at interrupting the mechanisms responsible for 
the generation of clinical pain. Breakthrough pain after surgical procedures is 
now beginning to be recognised as constituting suboptimal management. This 
is an active research area. A number of clinical trials have been conducted to 
prove the efficacy of anti-nociceptive effect of Ca2+ channel blockers using 
different techniques and different types of drugs with conflicting results. The 
use of epidural techniques also offer the advantage of allowing single shot 
injection of local anaesthetics and additives offering effective prolonged 
postoperative analgesia as compared to nerve blocks and local infiltrations21.  
 The altered sensory processing caused by high-intensity noxious stimuli 
has several possible mechanisms, including an expansion of receptive fields 
and a decrease in thresholds of dorsal horn neurons; an enhancement of 
responses of dorsal horn neurons elicited by repetitive C fiber stimuli, which is 
known as wind-up phenomenon; and an increase in dynorphine gene 
expression24, 4, 6. Repetitive fast - transmitter activity of aspartate and glutamate 
at α-amino-3-hydroxy- 5-methyl-4-isoxazolepropionic acid (AMPA)/ kinate 
receptors produces a membrane depolarization that counters a voltage-
dependent blockade of the NMDA receptor by Mg2+. Activation of  
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neurokinin-1 receptors by substance P produces a slow, prolonged 
depolarization and enhances the influx of extracellular Ca 2+ through voltage - 
operated Ca2+ channels. A further action of asparatate and glutamate on NMDA 
and metabotropic receptors produces an influx of Ca2+ through NMDA 
receptor-operated Ca 2+ channels and activates phospholipase C.  
 Phospholipase C  catalyzes the formation of intracellular second 
messengers, which causes the release of Ca2+ from the endoplasmic reticulum. 
The increase in intracellular Ca2+ produced by these reactions results in 
increased gene expression and central sensitization, including wind-up and 
long-term potentiation4. Thus, calcium channel conductance is required for the 
nervous system to signal a painful situation. A disruption of calcium ion 
movement interferes with sensory processing and contributes to antinociception  
 This series of reactions may be prevented or attenuated either 
presynaptically by reducing the release of neurotransmitters or postsynaptically 
by blocking specific receptors, such as NMDA receptor, or by both 
mechanisms. Opioids and local anesthetics reduce the presynaptic release of 
the neurotransmitters. 
 Calcium channel blockers have antinociceptive effects in  
animals12, 19 and show morphine potentiation in patients with chronic pain17. 
Substances with calcium channel-blocking effects and NMDA receptor 
antagonists may prevent pain and facilitate treatment of established pain  
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states 23. In this study, we found that bupivacaine and verapamil administered 
epidurally, reduced the amount of analgesic that patients required 
postoperatively suggesting that verapamil may prevent central sensitization by 
surgical trauma.  
 In this double blind study, we have evaluated the analgesic efficacy of 
bupivacaine with verapamil mixture given through lumbar epidural route in 
patient undergoing elective orthopaedic lower limb surgeries.  
 Pain intensity was assessed using the verbal rating scale (VRS). 
Significant lower VRS scores after 2, 6, 12,24 & 48 hours has demonstrated the 
clinical advantage of administering a mixture of bupivacaine and verapamil 
through lumbar epidural route for effective postoperative analgesia.  
 Duration of analgesia was significantly more in group V patients 
receiving bupivacaine and verapamil mixture (6.42 ± 0.63 hours) as compared 
to group P (3.84 ± 0.46 hours). The demand for supplementary analgesic doses 
over 48 hours postoperatively was significantly low in group V (4.25 ± 0.44 
doses) than group P (6.35 ± 0.49 doses). 
Bradycardia with a heart rate < 60/ min was not encountered in any of 
the patient in both the groups.  
Two patients of placebo group (10% of Group P) and one patient of 
verapamil group (5% of Group V) had episodes of hypotension with a MAP 
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<65 mm Hg during intraoperative period who were managed with a single dose 
of ephedrine 6 mg IV and crystalloids probably as a result of epidural 
anaesthesia as such.  
Postoperatively two patients of placebo group (10% of Group P) and one 
patient of verapamil group (5% of Group V) had episodes of hypotension with 
a MAP <65 mm Hg. These patients were found to have an excessive blood loss 
seen in the operative  site wound drain, who were managed with compatible 
whole blood transfusion. No incidence of any bradycardia was noted in both 
the groups during postoperative period.  
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SUMMARY 
 This randomised double blind study was designed to evaluate the 
analgesic efficacy of bupivacaine with verapamil mixture given through lumbar 
epidural route for postoperative analgesia in patients undergoing elective 
orthopaedic lower limb surgeries and the quality of analgesia was compared 
with epidural plain bupivacaine.  
Forty ASA I & II patients undergoing elective orthopaedic lower limb 
surgical procedure under epidural anaesthesia were randomly allocated in a 
double blinded fashion to one of the two groups. Group P received 2 ml of 
normal saline along with first dose of 14 ml 0.5% bupivacaine. Group V 
received 2 ml (5 mg) of injection verapamil along with the first dose of 14 ml 
0.5 % bupivacaine. 
Pain in the postoperative period was assessed using a verbal rating scale 
(VRS). Pain score were significantly less in group V at 2, 6, 12, 48 hours (P < 
0.05) than in group P. Overall pain score over 48 hours period also revealed 
better pain relief in group V (P<0.05) as compared to Group P. Time of first 
rescue analgesic (TFA) and the supplementary analgesic doses required for 48 
hours were noted for the two groups. 
Time of first rescue analgesic (TFA) in group V (6. 42 ±0.63 hours) was 
significantly prolonged compared with group P (3.84 ± 0.46 hours). The 
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postoperative analgesic consumption was also significantly less in Group V 
(4.25 doses for 48 hours) than in Group P (6.35 doses for 48 hours). The 
incidence of hypotension did not differ significantly between the two groups & 
there was no bradycardia in both the groups.  
So this study demonstrates that addition of verapamil to bupivacaine 
definitely improves the quality of analgesia by reducing the over all pain score, 
prolonging the duration of the time of first rescue analgesia (TFA) and causing 
reduction of total analgesic consumption in the post operative period without 
any hemodynamic instability.  
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CONCLUSION 
1. Single dose administration of verapamil and bupivacaine mixture 
given through lumbar epidural route provides effective postoperative 
analgesia in patients undergoing elective orthopaedic lower limb 
surgeries, without any hemodynamic instability.  
2. Epidural verapamil significantly reduces the postoperative analgesic 
consumption.  
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PROFORMA 
 
Name  :  Height  : 
     
Age  : Sex : Weight : 
     
I.P.No. :  Diagnosis : 
     
ASA Status :  Surgery : 
     
Group :  Duration of Surgery : 
 
Time of Injection of drugs:  Epidural 1st dose- 
       
     Dose of Verapamil or Placebo- 
 
     Epidural 2nd dose- 
 
     Epidural 3rd dose- 
 
Time of incision  
 
 
 
INTRA – OPERATIVE  VITALS MONITORING 
Time interval (minutes) 
Sl.
No 
Parameter Pre-op 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 
1. HR                 
2. SBP                 
3. DBP                 
4. MAP                 
5. RR                 
  
Intra – operative events: 
 
 POST –OPERATIVE  MONITORING 
Parameter Time interval (hours) 
 2 hrs 6 hrs 12 hrs 24 hrs 48 hrs 
1. Pain Score : (Verbal 
     Rating Scale) 
      0 - No Pain  
      1 – Mild Pain 
      2 – Moderate Pain 
      3 -  Severe Pain  
 
 
2. Adverse Effects: 
 Hypotension 
 Bradycardia       
     
 
 
POST –OPERATIVE ANALGESICS CONSUMPTION 
 
1.  Time of First 
 Rescue analgesic : 
 (TFA in hours) 
 
2. No.of Supplementary  
 analgesic doses required  
 (for 48 hours) 
 
 
